OpenAI Offers U.S. Academic Labs Free GPT-Rosalind Access Under New Plan

What the plan includes

According to OpenAI, GPT-Rosalind combines frontier reasoning with Rosalind Workbench, which enables specialized tool orchestration across medicinal chemistry, genomics, wet-lab assistance and other scientific applications. The new plan is meant to bring that combination to more academic scientists.

Eligible labs receive the following:

• Up to 30 Business Standard seats at $0 per user per month for up to 12 months.
• Access to all commercially available frontier OpenAI models, subject to plan usage limits.
• Access to GPT-Rosalind following trusted-access approval.

OpenAI states that research data shared through the Rosalind Academic Plan is not used to train its models by default. API access is not included at this time.

Who can apply and how

The plan is currently available to academic labs at U.S. universities. Principal investigators and lab leads at universities without an OpenAI Enterprise agreement can apply on behalf of their labs through OpenAI's trusted access process. Labs at universities that already have an agreement must apply through their university's Enterprise access process.

Once approved, PIs and lab leads can activate free access to GPT-Rosalind for up to 30 named members, alongside the other frontier models in the plan. Verified PIs and lab leads manage member permissions and are responsible for their lab's approved use. OpenAI points applicants to a help center guide for details on eligibility and application requirements.

Safeguards and trusted access

GPT-Rosalind is described as a specialized life sciences model built for deeper reasoning on complex biological questions. Through trusted access, approved researchers can investigate sensitive scientific questions within safeguards designed for legitimate research. One listed area of work is drug and protein design, which covers candidate drugs, therapeutic proteins, peptides and enzymes.

Before activating access, OpenAI says it verifies the institution's legitimacy and the identity of the PI or lab lead. It also reviews the lead's professional background, institutional appointment and authority to oversee lab access, and assesses the lab's affiliation, research activities and intended use. It establishes clear responsibilities for the lab lead and a designated institutional safety contact.

Safeguards continue after activation through monitoring and enforcement. For registered high-sensitivity use cases, OpenAI says its safety checks account for the approved research context, and it may follow up with researchers to clarify the work and confirm authorization. The company says this approach is designed to detect potential misuse while reducing unnecessary interruptions to authorized work.

An example comparison

OpenAI's announcement includes a case on designing antiviral therapeutics. In it, the company says GPT-Rosalind provided a candidate comparison matrix, a modeling plan and paired study plans, with controls and interpretation guidance addressing the lead's uneven performance. A mainline model, labeled Astra, withheld actionable parts of the request, such as specific candidate designs and implementation-level experimental plans, and offered only high-level modeling context and qualitative artifact checks.

OpenAI notes that these assessments address textual fulfillment of the requested deliverables. They do not verify scientific correctness, feasibility, or whether a method works.

What it means for academic research

OpenAI frames the plan as part of a broader effort to put AI tools in the hands of more scientists, starting with academic labs. The company says that lowering the cost of access should give more researchers room to pursue ideas that could lead to a clearer understanding of disease, better treatments and more resilient food systems. It adds that distinguished academic labs are already exploring GPT-Rosalind for work ranging from protein design to understanding neurodegeneration.

For eligible U.S. labs, the offer removes seat costs for up to a year, though GPT-Rosalind itself remains gated by approval, and labs that need API access will not find it in this plan for now.